What are key trade-offs in HIV drug resistance assays? Sanger vs NGS vs Proviral DNA

The fundamental technical choice in HIV drug resistance assay development comes down to how deeply you need to see into the viral population and what kind of sample you can realistically obtain. Sanger sequencing offers a simple, well-validated workflow but detects only dominant variants present at ≥20–30% frequency, requiring a viral load of at least 500–2000 copies/mL. Next‑generation sequencing (NGS) pushes detection down to ≤1%, revealing minority resistant quasispecies that Sanger misses. When viral load is suppressed and RNA is unavailable, proviral DNA from infected cells becomes a target—but it captures archived sequences that may not represent the actively replicating virus guiding current treatment.

The core trade-off is between sensitivity and clinical immediacy: Sanger is inexpensive and proven for routine resistance screening in viremic patients, NGS excels at detecting low-frequency resistant clones that could fuel future failure, while proviral DNA solves the sample-availability problem at the risk of flagging historical mutations no longer circulating. The assay’s intended use—routine surveillance versus deep minority variant detection—dictates which platform and nucleic acid target you should build on.

The Sensitivity Spectrum: Sanger vs. NGS

Sanger Sequencing: Established but Limited Sensitivity

Sanger sequencing is the historical gold standard, but its analytical floor is high.
It reliably calls a drug resistance mutation only when that mutant comprises approximately 20–30% of the viral population.
In practice, this means a resistant clone present at 15% in a mostly wild‑type background will typically go undetected.

This limit is coupled with a viral load threshold of 500–2000 copies/mL.
Below that input amount, the sequencing reaction lacks sufficient template, rendering results unreliable.
For diagnostic developers, Sanger’s advantage lies in its workflow simplicity, low reagent cost, and mature IVD infrastructure—but it sacrifices the ability to see emerging resistance below the dominant swarm.

Next-Generation Sequencing: Uncovering Minority Variants

NGS overcomes the population‑sensitivity barrier by sequencing millions of individual molecules.
Deep‑sequencing workflows reliably detect mutations down to 1% representation, and even lower with high‑coverage panels.
This capability is critical because low‑abundance resistant quasispecies can expand under drug pressure and cause virological failure—even when conventional genotyping reports a susceptible virus.

NGS also resolves technical limitations that muddy Sanger reads: it eliminates heterozygous phasing ambiguities, removes sequence gaps in unsequenced gene regions, and enables multiplex sample indexing for high‑throughput labs.
The cost is greater complexity: library preparation, bioinformatics pipelines, and specialized reagents demand more robust quality control and investment.
However, for markets where detecting early resistance signals is paramount, NGS’s sensitivity makes it the platform of choice.

The Target Dilemma: RNA vs. Proviral DNA

RNA Targets Reflect Active Replication

Sequencing plasma HIV‑1 RNA captures the currently circulating viral population.
This is the most clinically relevant snapshot for drug resistance, because it directly represents the variants that are actively replicating and causing disease.
The catch is that RNA‑based assays demand a detectable viral load.
When a patient is virologically suppressed (e.g., on effective ART), there is simply not enough circulating virus to extract, so RNA genotyping is impossible.

Proviral DNA Enables Testing in Suppressed Samples

When viral load is low or undetectable, proviral DNA—integrated into host cell genomes—can be amplified and sequenced.
This opens the door to resistance testing in patients who would otherwise have no result, such as those with intermittent adherence or those switching therapy in suppression.
Dried blood spots and other simplified collection matrices further expand access, making proviral DNA an attractive target for resource‑limited settings.

The Risk of Detecting Archived Resistance

The major limitation of proviral DNA is that it represents an archaeological record, not a real‑time census.
A proviral sequence may harbor resistance mutations that were present years ago but are no longer part of the replicating viral pool.
If an assay flags these archived mutations as current, clinicians may unnecessarily escalate therapy.
Diagnostic developers must therefore decide whether their assay’s purpose is to identify past resistance history or to guide immediate treatment decisions—proviral DNA is excellent for the former, risky for the latter.

Understanding the Trade-offs: Cost, Throughput, and Clinical Relevance

Balancing Workflow Complexity Against Information Depth

Sanger sequencing remains the simplest and least expensive option for laboratories that only need to detect dominant resistance profiles in viremic patients.
It requires basic equipment and minimal data analysis, but it fails when you need to see the minority variants that foreshadow resistance.

NGS delivers rich, quantitative data on the entire viral swarm, but it demands high‑fidelity enzymes, targeted enrichment reagents, and sophisticated bioinformatics.
This makes it ideal for high‑resolution surveillance, clinical trials, or regional reference labs where spotting 1‑5% mutants can alter patient management.
The choice often comes down to whether you are deploying an assay for routine front‑line screening or for deep quasispecies characterization in complex cases.

Integrating Sample Types and Collection Matrices

If your assay must work across a continuum—from full viral load down to complete suppression—you may need to support both RNA and proviral DNA targets on the same platform.
NGS workflows can adapt to multiple input types, but the software and controls must be carefully designed to avoid misclassifying proviral-only mutations as active resistance.
Suppliers of IVD raw materials can help by providing customized master mixes and enrichment panels that maintain consistent performance whether the starting material is plasma RNA or cellular DNA.

Making the Right Choice for Your Assay

Your ultimate decision hinges on the clinical question you intend to answer and the infrastructure you have available.

• If your primary focus is routine resistance screening in viremic patients: Sanger sequencing on plasma RNA remains a cost-effective, validated choice. Its 20–30% sensitivity threshold is sufficient to catch dominant resistance that drives immediate drug selection.
• If your primary focus is detecting emerging resistance before it dominates: NGS on RNA is the necessary tool. Its ≤1% sensitivity reveals low‑frequency variants hidden from Sanger, providing an early warning system for treatment adaptation.
• If your primary focus is genotyping patients with suppressed or undetectable viral loads: Proviral DNA is the only viable nucleic acid target, but you must clearly communicate to end users that results reflect archived, not necessarily active, resistance.
• If your primary focus is building a flexible, future‑proof platform: Deploying an NGS workflow that can handle both RNA and proviral DNA—backed by robust bioinformatics—gives you the agility to address multiple clinical scenarios while managing the risk of over‑reporting historical mutations.

The right technology is not a universal answer; it’s the one that most accurately translates your assay’s clinical objective into a reproducible, actionable result.

Summary Table:

Whether you are designing routine Sanger screening, deep NGS quasispecies panels, or proviral DNA assays, CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-performance IVD raw materials, technical services, and expert consulting—supporting your assay at every stage from concept to clinic. Contact us today to accelerate your HIV molecular diagnostic development!